{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T04:01:22Z","timestamp":1793073682980,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.msard.2024.106244","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:07:09Z","timestamp":1736381229000},"page":"106244","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Recommendations on NMOSD treatment in Latin America: Utilizing consensus-based RAND\/UCLA methodology"],"prefix":"10.1016","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9955-8343","authenticated-orcid":false,"given":"Ricardo","family":"Alonso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar German","family":"Carnero Contentti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Fernando","family":"Hamuy Diaz de Bedoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethel","family":"Ciampi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berenice","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Zuluaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jefferson","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Ignacio","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Gracia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Zarco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Tkachuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Molt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibis","family":"Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramiro","family":"Fernandez Calderon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Patrucco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Trevi\u00f1o-Frenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyanira","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Navas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Fujihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Galleguillos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.msard.2024.106244_bib0001","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1177\/13524585211039750","article-title":"Dengue fever in a multiple sclerosis patient taking ocrelizumab: clinical commentary","volume":"27","author":"Alonso","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2024.106244_bib0002","doi-asserted-by":"crossref","unstructured":"Arvas A. Vaccination in patients with immunosuppression. Turk Pediatri Ars. 2014;49(3):181\u20135. doi: 10.5152\/tpa.2014.2206. PMID: 26078660; PMCID: PMC4462293.","DOI":"10.5152\/tpa.2014.2206"},{"key":"10.1016\/j.msard.2024.106244_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1166490","article-title":"Efficacy and safety of monoclonal antibody therapy in patients with neuromyelitis optica spectrum disorder: a systematic review and network meta-analysis","volume":"14","author":"Aungsumart","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2024.106244_bib0004","article-title":"SAkuraBONSAI: protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab","volume":"14","author":"Bennet","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2024.106244_bib0005","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fneur.2018.00888","article-title":"Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis","volume":"9","author":"Borisow","year":"2018","journal-title":"Front. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2024.106244_bib0006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241989","article-title":"Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States","volume":"15","author":"Bozio","year":"2020","journal-title":"PLoS. One"},{"issue":"1","key":"10.1016\/j.msard.2024.106244_bib0007","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies","volume":"18","author":"Carnero Contentti","year":"2021","journal-title":"J. Neuroinflammation."},{"issue":"4","key":"10.1016\/j.msard.2024.106244_bib0008","doi-asserted-by":"crossref","first-page":"74","DOI":"10.31083\/j.jin2304074","article-title":"Neuromyelitis optica spectrum disorder in latin america: state-of-the-art and current challenges","volume":"23","author":"Carnero Contentti","year":"2024","journal-title":"J. Integr. Neurosci."},{"key":"10.1016\/j.msard.2024.106244_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102428","article-title":"Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice","volume":"45","author":"Carnero Contentti","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"10","key":"10.1016\/j.msard.2024.106244_bib0010","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1177\/13524585231190248","article-title":"Rectifying global inequities in neuromyelitis optica diagnosis and treatment: a critical view from Latin America","volume":"29","author":"Carnero Contentti","year":"2023","journal-title":"Mult. Scler."},{"issue":"16","key":"10.1016\/j.msard.2024.106244_bib0011","doi-asserted-by":"crossref","first-page":"8638","DOI":"10.3390\/ijms22168638","article-title":"Treatment of neuromyelitis optica spectrum disorders","volume":"22","author":"Chan","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.msard.2024.106244_bib0012","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2024.106244_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1260358","article-title":"Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated disease: a review of prevalence and incidence worldwide","volume":"14","author":"Hor","year":"2023","journal-title":"Front. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2024.106244_bib0014","doi-asserted-by":"crossref","first-page":"7908","DOI":"10.3390\/ijms23147908","article-title":"Neuromyelitis optica spectrum disorder: from basic research to clinical perspectives","volume":"23","author":"Huang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.msard.2024.106244_bib0015","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2024.106244_bib0016","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis optica study group (NEMOS). Part II: attack therapy and long-term management","volume":"271","author":"K\u00fcmpfel","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2024.106244_bib0017","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) \u2013 revised recommendations of the Neuromyelitis optica study group (NEMOS). Part II: attack therapy and long-term management","volume":"271","author":"K\u00fcmpfel","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2024.106244_bib0018","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Lennon","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2024.106244_bib0019","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2024.106244_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577790","article-title":"Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: an update systematic review and meta-analysis","volume":"363","author":"Ma","year":"2022","journal-title":"J. Neuroimmunol."},{"issue":"5","key":"10.1016\/j.msard.2024.106244_bib0021","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S1474-4422(18)30040-1","article-title":"Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned","volume":"17","author":"Major","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2024.106244_bib0022","first-page":"20","article-title":"Sepsis and immunosenescence in the elderly patient: a review","volume":"4","author":"Mart\u00edn","year":"2017","journal-title":"Front. Med. (Lausanne)"},{"issue":"27","key":"10.1016\/j.msard.2024.106244_bib0023","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.msard.2024.106244_bib0024","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1177\/1352458517730131","article-title":"Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders","volume":"24","author":"Mealy","year":"2018","journal-title":"Mult Scler J"},{"key":"10.1016\/j.msard.2024.106244_bib0025","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1177\/1352458516678474","article-title":"Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders","volume":"23","author":"Montcuquet","year":"2017","journal-title":"Mult Scler J"},{"key":"10.1016\/j.msard.2024.106244_bib0026","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2024.106244_bib0027","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200124","article-title":"International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: recommendations for Eculizumab, Inebilizumab, and Satralizumab","volume":"10","author":"Paul","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"6","key":"10.1016\/j.msard.2024.106244_bib0028","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"93","author":"Pittock","year":"2023","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2024.106244_bib0029","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2024.106244_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103083","article-title":"Status of the neuromyelitis optica spectrum disorder in Latin America","volume":"53","author":"Rivera","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.106244_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104508","article-title":"Therapeutic strategies in NMOSD and MOGAD patients: a multicenter cohort study in Latin America","volume":"71","author":"Rojas","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2024.106244_bib0033","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000225","article-title":"Neuromyelitis optica spectrum disorders: comparison according to the phenotype and serostatus","volume":"3","author":"Sep\u00falveda","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.msard.2024.106244_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2020.101509","article-title":"Opportunistic tropical infections in immunosuppressed patients","volume":"34","author":"Shu Kurizky","year":"2020","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.msard.2024.106244_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104840","article-title":"Latin American consensus recommendations on the risk of infections in people with multiple sclerosis treated with disease modifying drugs","volume":"77","author":"Silva","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.106244_bib0036","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jns.2017.08.3005","article-title":"Prognostic factors for first relapse in Thai patients with neuromyelitis optica spectrum disorder","volume":"381","author":"Suksuchano","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2024.106244_bib0037","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2024.106244_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104485","article-title":"Barriers to access and unmet needs to neuromyelitis optica spectrum disorders care in an Argentinean cohort","volume":"70","author":"Tkachuk","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.106244_bib0039","doi-asserted-by":"crossref","unstructured":"Traboulsee A., Greenberg B.M., Bennett J.L., et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 2020.","DOI":"10.1016\/S1474-4422(20)30078-8"},{"key":"10.1016\/j.msard.2024.106244_bib0040","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2024.106244_bib0041","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology."},{"issue":"3","key":"10.1016\/j.msard.2024.106244_bib0042","article-title":"Efficacy and safety of monoclonal antibodies in neuromyelitis optica spectrum disorders: a survival meta-analysis of randomized controlled trials","volume":"2","author":"Xu","year":"2022","journal-title":"Adv. Ophthalmol. Pract. Res."},{"key":"10.1016\/j.msard.2024.106244_bib0043","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2024.106244_bib0044","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s00415-022-11364-9","article-title":"A real-world study of interleukin-6 receptor blockade in patients with neuromyelitis optica spectrum disorder","volume":"270","author":"Yang","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2024.106244_bib0045","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824008204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824008204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T09:15:58Z","timestamp":1740647758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824008204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":44,"alternative-id":["S2211034824008204"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.106244","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommendations on NMOSD treatment in Latin America: Utilizing consensus-based RAND\/UCLA methodology","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.106244","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106244"}}